Clinical Trial Update: Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating acalabrutinib plus pembrolizumab in advanced head and neck squamous cell carcinoma has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: COMPLETED | Results posted: 2019-09-12